HER-2/neu gene product in serum - An oncoprotein in the diagnosis and therapy of breast carcinoma

被引:0
|
作者
Schulze, G [1 ]
机构
[1] HELIOS Klinikum Berlin, Inst Lab Diagnost, D-13125 Berlin, Germany
关键词
breast cancer; Herceptin; HER-2; erb-B2; oncoprotein;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The HER-2/neu oncogene codes a protein of the family of epidermal growth factor receptors. The extracellular domain has a MW from 95-105 kDa and is shed into the blood. In some patients with malignant tumors there is a high expression of HER-2/neu connected with high levels of HER-2/neu protein in the serum. High concentrations signal aggressive growth, bad prognosis and shorter survival. The reference range lies between 4.0 and 14.0 ng/ml with a mean of 9.0 ng/ml There is a significant difference of values between patients with and without metastases, but not between healthy people and patients without metastases. The advantage of this parameter lies in the early diagnosis of recurrence in the therapy of metastasizing breast carcinomas especially on treatment with Herceptin.
引用
收藏
页码:1007 / 1010
页数:4
相关论文
共 50 条
  • [1] Expression of the HER-2/neu oncoprotein in serum in patients with renal cell carcinoma
    Rasmuson, T
    Grankvist, K
    Ljungberg, B
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 454 - 454
  • [2] Circulating levels of HER-2/neu oncoprotein in breast cancer
    Molina, Rafael
    Escudero, Jose M.
    Munoz, Montse
    Auge, Jose M.
    Filella, Xavier
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2012, 50 (01) : 5 - 21
  • [3] Assessment of Her-2/neu gene amplification status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining
    Mostafa, Naglaa A. E.
    Eissa, Saad S.
    Belal, Dalia M.
    Shoman, Soheir H.
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2011, 23 (01) : 41 - 46
  • [4] Monitoring therapy by serum HER-2/neu
    Schwartz, MK
    Smith, C
    Schwartz, DC
    Dnistrian, A
    Neiman, I
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2000, 15 (04): : 324 - 329
  • [5] Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer
    Carney, WP
    Neumann, R
    Lipton, A
    Leitzel, K
    Ali, S
    Price, CP
    CLINICAL CHEMISTRY, 2003, 49 (10) : 1579 - 1598
  • [6] Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours
    Pallud, C
    Guinebretiere, JM
    Guepratte, S
    Hacene, K
    Neumann, R
    Carney, W
    Pichon, MF
    ANTICANCER RESEARCH, 2005, 25 (2B) : 1433 - 1440
  • [7] HER-2/neu gene amplification in ductal carcinoma in situ of the breast
    Hoque, A
    Sneige, N
    Sahin, AA
    Menter, DG
    Bacus, JW
    Hortobagyi, GN
    Lippman, SM
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002, 11 (06) : 587 - 590
  • [8] HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma
    Hoang, MP
    Sahin, AA
    Ordòñez, NG
    Sneige, N
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 113 (06) : 852 - 859
  • [9] HER-2/NEU ONCOPROTEIN AS A PROGNOSTIC FACTOR IN BREAST-CANCER
    TOIKKANEN, S
    JOENSUU, H
    JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (11) : 1817 - 1817
  • [10] Targeted therapy in breast cancer -: The HER-2/neu gene and protein
    Ross, JS
    Fletcher, JA
    Bloom, KJ
    Linette, GP
    Stec, J
    Symmans, WF
    Pusztai, L
    Hortobagyi, GN
    MOLECULAR & CELLULAR PROTEOMICS, 2004, 3 (04) : 379 - 398